Breaking News

Financial Report: Alkermes 2Q12

Elan portfolio makes contribution

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes 2Q12  2Q Revenues: $72.0 million (+46%) 2Q Loss: $22.3 million (loss of $7.7 million 2Q11) Comments: Manufacturing and royalty revenues from Risperdal Consta were $44.3 million in the quarter, up 5%. Vivitrol sales were $9.9 million, compared to $6.5 million, up 52%. Alkermes completed the merger with Elan Drug Technologies (EDT) on Sept. 16, 2011. The EDT portfolio contributed $9.1 million to revenues in the quarter....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters